Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations-Reference-Cited by-同舟云学术

Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations

Published:2015-05-24 Issue:1 Volume:76 Page:155-161
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Inoue Yusuke,Inui Naoki,Asada Kazuhiro,Karayama Masato,Matsuda Hiroyuki,Yokomura Koshi,Koshimizu Naoki,Imokawa Shiro,Yamada Takashi,Shirai Toshihiro,Kasamatsu Norio,Suda Takafumi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-015-2784-x.pdf

Reference33 articles.

1. Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108

2. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66

3. Ershler WB, Longo DL (1997) Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst 89:1489–1497

4. Gridelli C, Shepherd FA (2005) Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest 128:947–957

5. Owonikoko TK, Ragin CC, Belani CP et al (2007) Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 25:5570–5577

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world study of first-line therapy with aumolertinib for elderly patients with non‑small cell lung cancer harboring EGFR mutation;2024-01-22

2. Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP);Lung Cancer;2023-12

3. Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer;Clinical and Translational Oncology;2023-08-11

4. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report;Journal of Geriatric Oncology;2022-11

5. A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study;The Oncologist;2022-10-01